Scholarlink

<p>The escalating crisis of antimicrobial resistance and biofilm-associated infections has fundamentally compromised conventional anti-infective therapy. Current antimicrobial agents for refractory infections face critical limitations, including systemic toxicity, inadequate tissue penetration, and the rapid emergence of multidrug resistance (MDR). As a promising strategy, cell-based drug delivery systems (CDDS) leverage living cells or their bioactive derivatives as sophisticated carriers to overcome these barriers. By harnessing innate biological functions, such as prolonged circulation, immune evasion, and active targeting, CDDS enhances therapeutic efficacy in preclinical models against refractory infections. This review systematically elaborates on CDDS platforms engineered from erythrocytes, immune cells, platelets, and stem cells, highlighting their unique mechanisms and advantages in anti-infective drug delivery. Furthermore, we critically evaluate the translational progress and future potential of CDDS in combating refractory infections, particularly those involving multidrug-resistant bacteria and biofilm-associated pathogens.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cell-based drug delivery for combating bacteria: focus on refractory infections

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月29日

查看全文
  • Weijing Cheng,
  • Nan Ding,
  • Ling Wu,
  • Tingrui Zhang,
  • Yu Liao,
  • Zongguang Tai,
  • Jing Tian,
  • Zhuo Wang

摘要

The escalating crisis of antimicrobial resistance and biofilm-associated infections has fundamentally compromised conventional anti-infective therapy. Current antimicrobial agents for refractory infections face critical limitations, including systemic toxicity, inadequate tissue penetration, and the rapid emergence of multidrug resistance (MDR). As a promising strategy, cell-based drug delivery systems (CDDS) leverage living cells or their bioactive derivatives as sophisticated carriers to overcome these barriers. By harnessing innate biological functions, such as prolonged circulation, immune evasion, and active targeting, CDDS enhances therapeutic efficacy in preclinical models against refractory infections. This review systematically elaborates on CDDS platforms engineered from erythrocytes, immune cells, platelets, and stem cells, highlighting their unique mechanisms and advantages in anti-infective drug delivery. Furthermore, we critically evaluate the translational progress and future potential of CDDS in combating refractory infections, particularly those involving multidrug-resistant bacteria and biofilm-associated pathogens.

Graphical abstract